Výsledky vyhledávání - "S, Bartholomeus"

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

Autor: Patrick Schöffski, Holger Fritsch, Patricia Glomb, Ahmad Awada, Pascal Wolter, Gerd Munzert, Herlinde Dumez, S. Bartholomeus, M. Taton, Thierry Gil

Publikováno v: European Journal of Cancer. 48:179-186

Background Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of vola

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b2bc7793c1a70de3cbeff2497f9d24f
https://doi.org/10.1016/j.ejca.2011.11.001

Zobrazit plný text záznamu

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Autor: Dominique de Valeriola, E. Brendel, Martine Piccart, Thierry Gil, M Mano, C. G. Haase, Brian Schwartz, S. Bartholomeus, Dirk Strumberg, Ahmad Awada, Alain Hendlisz

Publikováno v: British Journal of Cancer, 92 (10
British Journal of Cancer

BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour cell proliferation and tumour angiogenesis. This Phase I study was undertaken to determine the safety profile, maximum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbdf7ffc381de061c888c7a31dedc122
https://doi.org/10.1038/sj.bjc.6602584

Zobrazit plný text záznamu

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Autor: Ahmad Awada, Dan Liu, Herlinde Dumez, Marie-Anne Meeus, Korinna Pilz, Jessica Cescutti, Philippe Aftimos, Patrick Schöffski, Kathleen Forceville, Jo Costermans, S. Bartholomeus, Thierry Berghmans, Gerd Munzert

Publikováno v: Investigational New Drugs
Investigational new drugs, 33 (3

Summary: Background This trial evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1 inhibitor that induces mitotic arrest and apoptosis, combined with cisplatin or carboplati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174ae8e7400d3ce60dcf1ea68e818484
https://pubmed.ncbi.nlm.nih.gov/25794535

Zobrazit plný text záznamu

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer

Autor: Denis Larsimont, A. Di Leo, S. Rowan, Stella Dolci, A. Riva, K. Duffy, S. Bartholomeus, Marianne Paesmans, J.M. Nogaret, John Crown, Niall O'Higgins, Martine Piccart

Publikováno v: Annals of Oncology. 11:169-175

Summary Background and purpose Docetaxel is an active agent in the treatment of metastatic breast cancer. We evaluated the feasibility of docetaxel-based sequential and combination regimens as adjuvant therapies for patients with node-positive breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51b99a4c6f94b602758a02b142b08dcd
https://doi.org/10.1023/a:1008345432342

Zobrazit plný text záznamu

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours

Autor: Martin Radtke, Fabienne Lebrun, E. Brendel, Chetan Lathia, Olaf Christensen, Thierry Delaunoit, Dominique de Valeriola, Martine Piccart-Gebhart, Alain Hendlisz, Thierry Gil, S. Bartholomeus, Ahmad Awada

Publikováno v: European journal of cancer (Oxford, England : 1990). 48(4)

Aim The safety, pharmacokinetics and efficacy of sorafenib plus docetaxel in patients with advanced refractory cancer were investigated in a Phase I, dose-escalation trial. Methods Twenty-seven patients in four Cohorts received docetaxel on Day 1 (Co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::262a22c2ec0a0f9951dd4840ef0a6c94
https://pubmed.ncbi.nlm.nih.gov/22285181

Zobrazit plný text záznamu

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(12)

PURPOSE: To compare a full-dose epirubicin-cyclophosphamide (HEC) regimen with classical cyclophosphamide, methotrexate, and fluorouracil (CMF) therapy and with a moderate-dose epirubicin-cyclophosphamide regimen (EC) in the adjuvant therapy of node-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74850deab8e554806a12c742e1c7a9f7
https://pubmed.ncbi.nlm.nih.gov/11408507

Zobrazit plný text záznamu

A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors

Autor: E, Van Den Neste, D, de Valeriola, J, Kerger, H, Bleiberg, Z, Kusenda, C, Brassinne, S, Bartholomeus, J, Selleslags, P, Hennebert, H, Wythouck, I, Cazenave, F, Lefresne-Soulas, M, Piccart

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(1)

Encouraged by preclinical synergism between docetaxel and 5-fluorouracil (5FU), we conducted a Phase I study of docetaxel in combination with continuous i.v. infusion of 5FU in patients with advanced solid tumors to determine the maximum tolerated do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::156a2dc00d533aab922ed67c9d318e51
https://pubmed.ncbi.nlm.nih.gov/10656433

Zobrazit plný text záznamu

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

Autor: José Thomas, Ahmad Awada, P. O. Witteveen, Jan H. Schornagel, Peter F. Bruning, Robert Paridaens, Martine Piccart, E. Tomiak, J. Wildiers, S. Bartholomeus

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 6(7)

BACKGROUND: In an attempt to increase chemotherapy dose intensity by step-wise reduction of the time interval between treatment cycles, filgrastim was administered to breast cancer patients receiving a three-month combination chemotherapy with epirub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06c247e976c1c390bb5b740acaea07bd
https://pubmed.ncbi.nlm.nih.gov/8664188

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání